NCT01600469View on ClinicalTrials.gov

NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Alzheimer's DiseaseMild Cognitive Impairment
Interventions
DRUG

DAOI-B

250-1500 mg/day, oral, for 24 weeks

OTHER

Placebo

placebo, oral, for 24 weeks

Trial Locations (1)

886

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT01600469 - NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter